<sup>68</sup>Ga-FAPI在疾病诊疗中的应用

张晓瑶; 方琪; 王欣璐; 张晓瑶; 方琪; 王欣璐

doi:10.3760/cma.j.cn121381-202006019-00056

[1]

Kratochwil C, Flechsig P, Lindner T, et al. ⁶⁸Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J]. J Nucl MedJ Nucl Med, 2019, 60(6): 801-805. doi: 10.2967/jnumed.119.227967

[2]

Giesel FL, Kratochwil C, Lindner T, et al. ⁶⁸Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers[J]. J Nucl MedJ Nucl Med, 2019, 60(3): 386-392. doi: 10.2967/jnumed.118.215913

[3]

Rettig WJ, Chesa PG, Beresford HR, et al. Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets[J]. Cancer ResCancer Res, 1986, 46(12 Pt 1): 6406-6412.

[4]

Jacob M, Chang L, Puré E. Fibroblast activation protein in remodeling tissues[J]. Curr Mol MedCurr Mol Med, 2012, 12(10): 1220-1243. doi: 10.2174/156652412803833607

[5]

Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy[J]. Mol Cancer TherMol Cancer Ther, 2012, 11(2): 257-266. doi: 10.1158/1535-7163.Mct-11-0340

[6]

Shiga K, Hara M, Nagasaki T, et al. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth[J/OL]. Cancers, 2015, 7(4): 2443−2458[2020-06-10]. https://doi.org/10.3390/cancers7040902. DOI: 10.3390/cancers7040902.

[7]

Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy[J]. Proteomics Clin ApplProteomics Clin Appl, 2014, 8(5/6): 454-463. doi: 10.1002/prca.201300095

[8]

Chen WT, Kelly T. Seprase complexes in cellular invasiveness[J]. Cancer Metastasis RevCancer Metastasis Rev, 2003, 22(2/3): 259-269. doi: 10.1023/a:1023055600919

[9]

Keane FM, Nadvi NA, Yao TW, et al. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α[J]. FEBS JFEBS J, 2011, 278(8): 1316-1332. doi: 10.1111/j.1742-4658.2011.08051.x

[10]

Loeffler M, Krüger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake[J]. J Clin InvestJ Clin Invest, 2006, 116(7): 1955-1962. doi: 10.1172/jci26532

[11]

Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α[J]. ScienceScience, 2010, 330(6005): 827-830. doi: 10.1126/science.1195300

[12]

Santos AM, Jung J, Aziz N, et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice[J]. J Clin InvestJ Clin Invest, 2009, 119(12): 3613-3625. doi: 10.1172/jci38988

[13]

Egger C, Cannet C, Gérard C, et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis[J]. Eur J PharmacolEur J Pharmacol, 2017, 809: 64-72. doi: 10.1016/j.ejphar.2017.05.022

[14]

Tillmanns J, Hoffmann D, Habbaba Y, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction[J]. J Mol Cell CardiolJ Mol Cell Cardiol, 2015, 87: 194-203. doi: 10.1016/j.yjmcc.2015.08.016

[15]

Puré E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics[J]. OncogeneOncogene, 2018, 37(32): 4343-4357. doi: 10.1038/s41388-018-0275-3

[16]

Chen HJ, Pang YZ, Wu JX, et al. Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F]FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2020, 47(8): 1820-1832. doi: 10.1007/s00259-020-04769-z

[17]

Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein[J]. J Nucl MedJ Nucl Med, 2018, 59(9): 1415-1422. doi: 10.2967/jnumed.118.210443

[18]

Giesel FL, Heussel CP, Lindner T, et al. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(8): 1754-1755. doi: 10.1007/s00259-019-04346-z

[19]

Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts[J]. J Nucl MedJ Nucl Med, 2018, 59(9): 1423-1429. doi: 10.2967/jnumed.118.210435

[20]

Meyer C, Dahlbom M, Lindner T, et al. Radiation dosimetry and biodistribution of ⁶⁸GA-FAPI-46 PET imaging in cancer patients[J]. J Nucl MedJ Nucl Med, 2020, 61(8): 1171-1177. doi: 10.2967/jnumed.119.236786

[21]

Chen HJ, Zhao L, Ruan D, et al. ⁶⁸Ga-FAPI PET/CT improves therapeutic strategy by detecting a second primary malignancy in a patient with rectal cancer[J]. Clin Nucl MedClin Nucl Med, 2020, 45(6): 468-470. doi: 10.1097/rlu.0000000000003000

[22]

Lindner T, Altmann A, Krämer S, et al. Design and development of ^99mTc labeled FAPI-tracers for SPECT-Imaging and ¹⁸⁸Re therapy[J]. J Nucl MedJ Nucl Med, 2020, 61(10): 1507-1513. doi: 10.2967/jnumed.119.239731

[23]

Khreish F, Rosar F, Kratochwil C, et al. Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2020, 47(8): 2040-2041. doi: 10.1007/s00259-019-04623-x

[24]

Koerber SA, Staudinger F, Kratochwil C, et al. The role of ⁶⁸Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience[J]. J Nucl MedJ Nucl Med, 2020, 61(9): 1331-1336. doi: 10.2967/jnumed.119.237016

[25]

Voltin CA, Mettler J, Grosse J, et al. FDG-PET imaging for Hodgkin and diffuse large B-cell lymphoma— an updated overview[J/OL]. Cancers, 2020, 12(3): 601[2020-06-10]. https://www.mdpi.com/2072-6694/12/3/601. DOI: 10.3390/cancers12030601.

[26]

Brokopp CE, Schoenauer R, Richards P, et al. Fibroblast activation protein is induced by inflammation and degrades typeⅠcollagen in thin-cap fibroatheromata[J]. Eur Heart JEur Heart J, 2011, 32(21): 2713-2722. doi: 10.1093/eurheartj/ehq519

[27]

Meletta R, Müller Herde A, Chiotellis A, et al. Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging[J/OL]. Molecules, 2015, 20(2): 2081−2099[2020-06-10]. https://www.mdpi.com/1420-3049/20/2/2081. DOI: 10.3390/molecules20022081.

[28]

Laverman P, van der Geest T, Terry SYA, et al. Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis[J]. J Nucl MedJ Nucl Med, 2015, 56(5): 778-783. doi: 10.2967/jnumed.114.152959

[29]

van der Geest T, Laverman P, Gerrits D, et al. Liposomal treatment of experimental arthritis can be monitored noninvasively with a radiolabeled anti-fibroblast activation protein antibody[J]. J Nucl MedJ Nucl Med, 2017, 58(1): 151-155. doi: 10.2967/jnumed.116.177931

[30]

Varasteh Z, Mohanta S, Robu S, et al. Molecular imaging of fibroblast activity after myocardial infarction using a ⁶⁸Ga-labeled fibroblast activation protein inhibitor, FAPI-04[J]. J Nucl MedJ Nucl Med, 2019, 60(12): 1743-1749. doi: 10.2967/jnumed.119.226993

[31]

Sonni I, Lee-Felker S, Memarzadeh S, et al. ⁶⁸Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(3): 924-926. doi: 10.1007/s00259-020-04947-z

[32]

Hao B, Wu XR, Pang YZ, et al. [¹⁸F]FDG and [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(2): 651-652. doi: 10.1007/s00259-020-04941-5

[33]

Luo YP, Pan QQ, Zhang W. IgG4-related disease revealed by ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(12): 2625-2626. doi: 10.1007/s00259-019-04478-2

[34]

Pan QQ, Luo YP, Zhang W. Recurrent immunoglobulin G4-related disease shown on ¹⁸F-FDG and ⁶⁸Ga-FAPI PET/CT[J]. Clin Nucl MedClin Nucl Med, 2020, 45(4): 312-313. doi: 10.1097/RLU.0000000000002919

[35]

Luo YP, Pan QQ, Yang HX, et al. Fibroblast activation protein-targeted PET/CT with ⁶⁸Ga-FAPI for imaging IgG4-related disease: comparison to ¹⁸F-FDG PET/CT[J]. J Nucl MedJ Nucl Med, 2021, 62(2): 266-271. doi: 10.2967/jnumed.120.244723

[36]

Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases[J]. Am J Surg PatholAm J Surg Pathol, 2010, 34(12): 1812-1819. doi: 10.1097/PAS.0b013e3181f7266b

[37]

Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase Ⅱtrial of sibrotuzumab in patients with metastatic colorectal cancer[J]. OnkologieOnkologie, 2003, 26(1): 44-48. doi: 10.1159/000069863

[38]

姚兰琳, 吴华, 郭崴. 乳腺癌核素靶向诊疗一体化的研究进展[J]. 国际放射医学核医学杂志, 2020, 44(11): 728-735. doi: 10.3760/cma.j.cn121381-201909026-00081
Yao LL, Wu H, Guo W. Research progress in integrated radionuclide targeted diagnosis and treatment of breast cancer[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2020, 44(11): 728-735. doi: 10.3760/cma.j.cn121381-201909026-00081

[39]

Watabe T, Liu YW, Kaneda-Nakashima K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma:⁶⁴Cu- and ²²⁵Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models[J]. J Nucl MedJ Nucl Med, 2020, 61(4): 563-569. doi: 10.2967/jnumed.119.233122

[40]

Lo A, Wang LCS, Scholler J, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells[J]. Cancer ResCancer Res, 2015, 75(14): 2800-2810. doi: 10.1158/0008-5472.Can-14-3041

[41]

Puré E, Lo A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors?[J]. Cancer Immunol ResCancer Immunol Res, 2016, 4(4): 269-278. doi: 10.1158/2326-6066.Cir-16-0011

[42]

黄超群, 耿霞飞, 刘九洋, 等. 间质成纤维细胞激活蛋白对胃癌细胞SGC7901生物学行为的作用[J]. 武汉大学学报: 医学版, 2020, 41(1): 39-43. doi: 10.14188/j.1671-8852.2019.0042
Huang CQ, Geng XF, Liu JY, et al. Effect of stromal fibroblast activation protein alpha on the biological behaviors of gastric cancer cell SGC7901[J]. Med J Wuhan UnivMed J Wuhan Univ, 2020, 41(1): 39-43. doi: 10.14188/j.1671-8852.2019.0042

[43]

唐婷婷. 成纤维细胞激活蛋白对卵巢癌细胞增殖和凋亡的影响[J]. 中国现代医生, 2019, 57(36): 34-36.
Tang TT. Effect of fibroblast activation protein on proliferation and apoptosis of ovarian cancer cell[J]. China Mod DoctorChina Mod Doctor, 2019, 57(36): 34-36.